Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3333303 | Revue d'Oncologie Hématologie Pédiatrique | 2014 | 13 Pages |
Abstract
ICH is a serious and unpredictable event. Early treatment does not seem to prevent it. One should always look after suggestive clinical signs of this complication, as it requires a prompt management including immunoglobulins, steroids and platelet infusions. The use of thrombopoietin receptor agonists and other drugs still has to be defined.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
C. Sevrez, S. Thouvenin, B. Choppard, F. Fouyssac, F. Baleydier, H. Chambost, F. Demeocq, D. Plantaz, P. Girard, C. Guitton, A. Boutmy, B. Lescoeur, W. Abouchahla, A.F. Derache, G. Leverger, N. Aladjidi, J.L. Stephan,